STAT3 and hepatocellular carcinoma: TTI-101, a small-molecule STAT3 inhibitor that competitively targets the phosphotyrosyl peptide-binding pocket in the Src homology 2 (SH2) domain of STAT3, has shown anti-HCC activities [35,36] and received orphan drug designation for HCC.